• Something wrong with this record ?

Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes

V. Vymetalkova, P. Soucek, T. Kunicka, K. Jiraskova, V. Brynychova, B. Pardini, V. Novosadova, Z. Polivkova, K. Kubackova, R. Kozevnikovova, M. Ambrus, L. Vodickova, A. Naccarati, P. Vodicka,

. 2015 ; 10 (7) : e0134463. [pub] 20150730

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020461

Grant support
NT13424 MZ0 CEP Register
NT14055 MZ0 CEP Register

Variations in the TP53 gene have been suggested to play a role in many cancers, including breast. We previously observed an association between TP53 haplotypes based on four polymorphisms (rs17878362, rs1042522, rs12947788, and rs17884306) and the risk of colorectal and pancreatic cancer. Based on these results, in the present study, we have investigated the same polymorphisms and their haplotypes in 705 breast cancer cases and 611 healthy controls in relation to the disease risk, histopathological features of the tumor and clinical outcomes. In comparison to the most common haplotype A1-G-C-G, all the other identified haplotypes were globally associated with a significantly decreased breast cancer risk (P = 0.006). In particular, the A2-G-C-G haplotype was associated with a marked decreased risk of breast cancer when compared with the common haplotype (P = 0.0001). Moreover, rs1042522 in patients carrying the GC genotype and receiving only the anthracycline-based chemotherapy was associated with both overall and disease-free survival (recessive model for overall survival HR = 0.30 95% CI 0.11-0.80, P = 0.02 and for disease-free survival HR = 0.42 95% CI 0.21-0.84, P = 0.01). Present results suggest common genetic features in the susceptibility to breast and gastrointestinal cancers in respect to TP53 variations. In fact, similar haplotype distributions were observed for breast, colorectal, and pancreatic patients in associations with cancer risk. Rs1042522 polymorphism (even after applying the Dunn-Bonferroni correction for multiple testing) appears to be an independent prognostic marker in breast cancer patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020461
003      
CZ-PrNML
005      
20191030131356.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0134463 $2 doi
024    7_
$a 10.1371/journal.pone.0134463 $2 doi
035    __
$a (PubMed)26226484
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vymetálková, Veronika $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine Charles University, Prague, Czech Republic. $7 xx0102721
245    10
$a Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes / $c V. Vymetalkova, P. Soucek, T. Kunicka, K. Jiraskova, V. Brynychova, B. Pardini, V. Novosadova, Z. Polivkova, K. Kubackova, R. Kozevnikovova, M. Ambrus, L. Vodickova, A. Naccarati, P. Vodicka,
520    9_
$a Variations in the TP53 gene have been suggested to play a role in many cancers, including breast. We previously observed an association between TP53 haplotypes based on four polymorphisms (rs17878362, rs1042522, rs12947788, and rs17884306) and the risk of colorectal and pancreatic cancer. Based on these results, in the present study, we have investigated the same polymorphisms and their haplotypes in 705 breast cancer cases and 611 healthy controls in relation to the disease risk, histopathological features of the tumor and clinical outcomes. In comparison to the most common haplotype A1-G-C-G, all the other identified haplotypes were globally associated with a significantly decreased breast cancer risk (P = 0.006). In particular, the A2-G-C-G haplotype was associated with a marked decreased risk of breast cancer when compared with the common haplotype (P = 0.0001). Moreover, rs1042522 in patients carrying the GC genotype and receiving only the anthracycline-based chemotherapy was associated with both overall and disease-free survival (recessive model for overall survival HR = 0.30 95% CI 0.11-0.80, P = 0.02 and for disease-free survival HR = 0.42 95% CI 0.21-0.84, P = 0.01). Present results suggest common genetic features in the susceptibility to breast and gastrointestinal cancers in respect to TP53 variations. In fact, similar haplotype distributions were observed for breast, colorectal, and pancreatic patients in associations with cancer risk. Rs1042522 polymorphism (even after applying the Dunn-Bonferroni correction for multiple testing) appears to be an independent prognostic marker in breast cancer patients.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádory prsu $x genetika $7 D001943
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny p53 $x genetika $7 D016158
650    _2
$a genetická predispozice k nemoci $x genetika $7 D020022
650    _2
$a genotyp $7 D005838
650    _2
$a haplotypy $x genetika $7 D006239
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jednonukleotidový polymorfismus $x genetika $7 D020641
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Souček, Pavel $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. $7 xx0060511
700    1_
$a Kunicka, Tereza $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Jiraskova, Katerina $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine Charles University, Prague, Czech Republic.
700    1_
$a Brynychová, Veronika $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Third Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0323150
700    1_
$a Pardini, Barbara $u Human Genetics Foundation, Turin, Italy. $7 _AN058834
700    1_
$a Novosadova, Vendula $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Polívková, Zdeňka $u Department of General Biology and Genetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0004229
700    1_
$a Kubáčková, Kateřina $u Department of Oncology, University Hospital Motol, Prague, Czech Republic. $7 xx0083614
700    1_
$a Kozevnikovova, Renata $u Department of Oncosurgery, MEDICON, Prague, Czech Republic.
700    1_
$a Ambrus, Miloslav $u Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. $7 gn_A_00005461
700    1_
$a Vodickova, Ludmila $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine Charles University, Prague, Czech Republic.
700    1_
$a Naccarati, Alessio $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Human Genetics Foundation, Turin, Italy.
700    1_
$a Vodička, Pavel $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine Charles University, Prague, Czech Republic. $7 xx0060269
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 7 (2015), s. e0134463
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26226484 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20191030131835 $b ABA008
999    __
$a ok $b bmc $g 1155131 $s 944989
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 7 $d e0134463 $e 20150730 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT13424 $p MZ0
GRA    __
$a NT14055 $p MZ0
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options